YXYi-Tao Xue

Yi-Tao Xue

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yi-Tao Xue has a total of 80 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Calycosin attenuates mitochondrial damage and pyroptosis in heart failure via the Nrf2/ROS/TXNIP pathway

    by Hua-Jing Yuan, Quan-Cheng Han, Yi-Ding Yu, Hui Yu, Xiu-Juan Liu, Yi-Tao Xue, Yan Li

    Heart failure (HF) is a key public health concern worldwide due to its high morbidity and mortality rates. Calycosin (CA) is a flavonoid natural product that effectively treats HF with cardioprotective effects; however, its mechanism of action remains unclear. The present study aimed to investigate the therapeutic effect of CA on HF and its mechanism through in vivo and in vitro experiments, and to reveal the roles of pyroptosis and mitochondrial dysfunction in the pathophysiology of HF. The HF model was constructed 4 weeks after ligation of the left anterior descending artery in rats. Myocardial ischemia‑reperfusion injury was simulated using a hypoxia‑reoxygenation model and nuclear factor erythroid 2‑related factor (Nrf2) was silenced by transfection using small interfering RNA to further explore the therapeutic mechanism of CA. The results revealed that CA treatment improved cardiac function and myocardial injury, suppressed oxidative stress levels and improved mitochondrial ultrastructure in HF‑induced rats. CA downregulated the expression of relevant pyroptosis proteins via the Nrf2/reactive oxygen species (ROS)/thioredoxin‑interacting protein (TXNIP) pathway. In vitro experiments demonstrated consistent results confirming that CA ameliorated mitochondrial damage by reducing levels of ROS and inhibiting mitochondrial gasdermin D N‑terminal fragments activation. Silencing Nrf2 partially reversed the cardioprotective effects of CA, confirming the key therapeutic role of CA in Nrf2‑mediated anti‑pyroptosis. In conclusion, CA inhibits pyroptosis and improves mitochondrial damage in HF through the Nrf2/ROS/TXNIP pathway, which may disrupt the crosstalk between mitochondrial damage and pyroptosis, thereby exerting cardioprotective effects.


  • Fuxin decoction regulates the Nrf2/SLC7A11/GPX4 pathway to ameliorate doxorubicin-induced ferroptosis in cardiomyocytes

    by Quancheng Han, Yonghong Guo, Yiding Yu, Jingle Shi, Huajing Yuan, Hui Yu, Xiujuan Liu, Yitao Xue, Yan Li

  • Open Access

    Identification of neutrophil extracellular traps-related genes for the diagnosis of acute myocardial infarction based on bioinformatics and experimental verification

    by Hua-Jing Yuan, Yi-Ding Yu, Wen-Wen Liu, Xiu-Juan Liu, Quan-Cheng Han, Jing-Le Shi, Yi-Tao Xue, Yan Li

    Neutrophil extracellular traps (NETs) have been demonstrated to play an important role in acute myocardial infarction (AMI), but their specific mechanisms in the development of AMI have not been investigated. The AMI datasets were screened from the GEO database. The hub genes in differentially expressed NET-related genes (DE-NRGs) were screened using bioinformatics and machine learning algorithms, and the nomogram model was constructed based on this. Functional enrichment analysis clarified the biological function and signaling pathways of NETs-mediated AMI. Immune infiltration analysis was performed on the AMI datasets. Finally, the AMI model was constructed using Wistar rats, evaluated by echocardiography and HE staining, and hub genes expression was verified by real-time quantitative PCR (RT-qPCR) and western blot. Based on the bioinformatics analysis, 23 DE-NRGs were obtained. The hub genes were screened by machine learning algorithms for NFIL3, MMP9 and S100A8. Immune infiltration analysis demonstrated the relative abundance of immune cells in the sample and their expression levels in hub genes. The experimental results showed that LVEF and FS were significantly reduced in the AMI group, cardiac function was impaired, and there were disturbances in the arrangement of cardiomyocytes and interstitial edema with inflammatory infiltration. NFIL3, MMP9 and S100A8 were significantly elevated in the AMI group compared to the Sham group. This study identified the hub genes of NETs-mediated AMI and constructed a diagnostic model through bioinformatics and experimental verification, which provided a new idea for the molecular mechanisms of AMI development and treatment.


  • Open Access

    Integrating bioinformatics and machine learning to investigate the mechanisms by which three major respiratory infectious diseases exacerbate heart failure

    by Yiding Yu, Quancheng Han, Juan Zhang, Jingle Shi, Huajing Yuan, Yitao Xue, Yan Li

    Heart failure (HF) is a severe cardiovascular disease often worsened by respiratory infections like influenza, COVID-19, and community-acquired pneumonia (CAP). This study aims to uncover the molecular commonalities among these respiratory diseases and their impact on HF, identifying key mediating genes. By performing differential expression analysis on GEO database data, we found 51 common molecules of three respiratory diseases. The gene module of HF was identified by weighted gene co-expression network analysis, and 10 characteristic genes of respiratory diseases that aggravate HF were obtained. GO and KEGG enrichment analysis showed that these genes were mainly involved in innate immune response, inflammation and coagulation pathways. By using three machine learning algorithms, LASSO, RF and SVM-RFE, we identified RSAD2 and IFI44L as key genes, and the Receiver Operating Characteristic (ROC) curve verification results showed high accuracy (Area Under the Curve, AUC > 0.7). ssGSEA showed that RSAD2 was involved in complement and coagulation cascade reactions, while IFI44L was related to myocardial contraction in the progression of heart failure. DSigDB prediction results showed that 6 drugs such as acetohexamide may have potential therapeutic effects on HF aggravated by respiratory diseases. Immune infiltration analysis revealed significant differences in eight immune cell types between HF patients and healthy controls. Our findings enhance the understanding of molecular interactions between respiratory diseases and heart failure, paving the way for future research and therapeutic strategies.


  • Open Access

    Mitochondrial dysfunction in AMI: mechanisms and therapeutic perspectives

    by Jingle Shi, Yiding Yu, Huajing Yuan, Yan Li, Yitao Xue

    Acute myocardial infarction (AMI) and the myocardial ischemia-reperfusion injury (MI/RI) that typically ensues represent a significant global health burden, accounting for a considerable number of deaths and disabilities. In the context of AMI, percutaneous coronary intervention (PCI) is the preferred treatment option for reducing acute ischemic damage to the heart. Despite the modernity of PCI therapy, pathological damage to cardiomyocytes due to MI/RI remains an important target for intervention that affects the long-term prognosis of patients. In recent years, mitochondrial dysfunction during AMI has been increasingly recognized as a critical factor in cardiomyocyte death. Damaged mitochondria play an active role in the formation of an inflammatory environment by triggering key signaling pathways, including those mediated by cyclic GMP-AMP synthase, NOD-like receptors and Toll-like receptors. This review emphasizes the dual role of mitochondria as both contributors to and regulators of inflammation. The aim is to explore the complex mechanisms of mitochondrial dysfunction in AMI and its profound impact on immune dysregulation. Specific interventions including mitochondrial-targeted antioxidants, membrane-stabilizing peptides, and mitochondrial transplantation therapies have demonstrated efficacy in preclinical AMI models.


  • Open Access

    Identification of Hub Genes for the Diagnosis Associated with Heart Failure Using Multiple Cell Death Patterns

    by Hua-Jing Yuan, Hui Yu, Yi-Ding Yu, Xiu-Juan Liu, Wen-Wen Liu, Yi-Tao Xue, Yan Li

    Aims: Heart failure (HF) is an important public health problem worldwide, and programmed cell death (PCD) plays a crucial role in its pathologic process. This study aims to identify the hub genes associated with HF through PCD in order to better understand the pathogenesis of HF and improve its diagnosis and treatment. Methods and results: The gene expression dataset of HF was obtained from the GEO database. Bioinformatics and machine learning algorithms were utilized to screen the HF key genes and PCD-related HF hub genes, and an HF diagnostic model was constructed on this. Functional enrichment analysis clarified the gene ontology and signalling pathways of HF. The immune infiltration analysis of HF was performed to explore the expression levels of immune cells in each hub gene. Through bioinformatics analysis, 95 HF key genes were obtained. Functional enrichment analysis showed that they were mainly involved in inflammation, immunomodulation and other mechanisms. DHRS11 and LRKK2 were identified as PCD-associated HF hub genes by machine learning algorithms. The hub genes were confirmed as significant biomarkers of HF in the training and validation datasets, and their constructed nomogram had effective diagnostic value. Immune infiltration analysis showed significant immune imbalance of T-cell populations, monocytes and macrophages M2 in HF. Conclusions: In this study, DHRS11 and LRKK2 were identified as hub genes. HF diagnostic model construction and immune infiltration analyses were performed, which provided new ideas for the molecular mechanisms of HF development and treatment.


  • Decoding the cytokine code for heart failure based on bioinformatics, machine learning and Bayesian networks

    by Yiding Yu, Xiujuan Liu, Wenwen Liu, Huajing Yuan, Quancheng Han, Jingle Shi, Yitao Xue, Yan Li


  • Open Access

    Exploration and verification of the therapeutic mechanism of shenfu injection in sepsis-induced myocardial injury

    by Hua-Jing Yuan, Guo-Han Xiang, Yang Liu, Yan Li, Wen-Li Liu, Jiu-Xiang Wei, Yi-Tao Xue, Hao Hao

    Background: Shenfu injection (SFI), derived from a traditional Chinese medicine (TCM) prescription, is an effective drug for the treatment of sepsis-induced myocardial injury (SIMI) with good efficacy, but its exact therapeutic mechanism remains unclear. Methods: SwissTargetPrediction and GeneCards database were used to obtain relevant targets for SFI and SIMI. STRING 11.5 and MCODE were used to analyse potential therapeutic targets for SFI. DAVID 6.8 database was used to perform enrichment analysis. In addition, the SIMI model was constructed by cecal ligation and puncture (CLP) on Sprague Dawley rats and the related protein expression levels were verified by AutoDock Vina 1.1.2 and experiment. Results: SFI has a total of 10 main active compounds and treats SIMI through 52 potential targets, among which LGALS3, STAT3, FGF1, and AKT1 were the core targets for treatment. Based on enrichment analysis, STAT3, FGF1, and AKT1 in the core targets were experimentally validated. The experimental results showed that SFI effectively ameliorated the inflammatory response and myocardial injury and inhibited apoptosis in SIMI. And SFI improved SIMI by decreasing caspase-9, STAT3 and phospho-AKT1 (p-AKT1) expression, and enhancing FGF1 expressions. Conclusions: This study showed that SFI effectively reduced the expression of caspase-9, STAT3 and p-AKT1, enhanced the expression of FGF1, reduced the inflammatory response, inhibited apoptosis and attenuated cardiac injury to SIMI.


  • Open Access

    Mechanistic Insights Into Qidan Yixin Decoction for Diabetic Cardiomyopathy via Macrophage Polarization

    by Yi Liu, Juan Zhang, Wei Gao, Quancheng Han, Yitao Xue, Xiujuan Liu

    Background: Diabetic cardiomyopathy (DCM) has a multifactorial etiology, and no specific treatment is available for its management. Qidan Yixin decoction (QDYXD) demonstrated encouraging clinical results in treating DCM; however, its underlying mechanics are yet unclear. Methods: Network pharmacology was applied to determine the active ingredients and targets of QDYXD. The GeneCards and GEO databases were used to retrieve genes associated with DCM and macrophage polarization. These targets were subjected to GO and KEGG enrichment analyses, immune infiltration study, and PPI network design. The core targets were further refined using SVM‐RFE, LASSO, and random forest algorithms. Docking the core targets with the main active components followed. For experimental validation, rat models were created. Results: There were 48 potential targets in all. Quercetin, methyl palmitate, luteolin, and tanshinone IIA were identified as the primary active components. Enrichment analysis indicated that one of the key pathways associated with the potential targets was the signaling pathway of HIF‐1. Machine learning techniques were used to identify two core targets, LDHA and PGK1. Animal experiments demonstrated that QDYXD can suppress the upregulation of PGK1, LDHA, and HIF1A; block the polarization of M1 macrophages; and considerably enhance DCM rats’ cardiac function. Conclusion: QDYXD improves cardiac function in DCM by attenuating M1 macrophage polarization and inhibiting the HIF‐1 signaling pathway, specifically through the modulation of PGK1, LDHA, and HIF1A. This study provides preliminary insights into how QDYXD modulates macrophage polarization during DCM treatment. Moreover, the identification of potential active components and core molecular targets of QDYXD offers promising directions for future drug development in DCM therapy.